Precious Metals

[gfp927z]

>>> Oppenheimer Starts F-Star Therapeutics Inc. (FSTX) at Outperform


StreetInsider.com

April 15, 2021


https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Oppenheimer+Starts+F-Star+Therapeutics+Inc.+%28FSTX%29+at+Outperform/18268042.html?classic=1


Oppenheimer analyst Jartaj Singh initiates coverage on F-Star Therapeutics Inc. (NASDAQ: FSTX) with a Outperform rating and a price target of $30.00.

The analyst comments "We are initiating coverage on F-star Therapeutics (FSTX) with an Outperform rating and a $30 PT. We believe FSTX screens well among various bispecific antibody (BsAbs) platforms evolving rapidly in the past two years, given the company platform's ability to leverage the three key features of BsAbs: conditionality / crosslinking / clustering through its molecules' Fc-gamma receptor (Fc?R) independent tetravalent binding and generate uncorrelated high-value oncology assets. In our opinion, FSTX's story has checked the boxes for:

(1) a biomarker-driven targeted oncology approach identifying a patient population subset that allows accelerated approval;

(2) enhanced risk/benefit profile with low immunogenicity/high-affinity target engagement/no hook effect/etc.;

(3) unveiling novel target synergy unattainable by mAbs combination; and

(4) experienced/execution-focused management. We are bullish on the story."

For an analyst ratings summary and ratings history on F-Star Therapeutics Inc. click here. For more ratings news on F-Star Therapeutics Inc. click here.

Shares of F-Star Therapeutics Inc. closed at $9.85 yesterday.

<<<